Moderna Stock Nearly Triples on Cancer Vaccine Trial
Moderna shares surged 177% after its personalized mRNA cancer vaccine met Phase 3 endpoints in melanoma, marking a historic milestone for cancer treatment.
Tag
6 articles
Moderna shares surged 177% after its personalized mRNA cancer vaccine met Phase 3 endpoints in melanoma, marking a historic milestone for cancer treatment.
Moderna and Merck announce their mRNA-based cancer vaccine intismeran met key endpoints in a Phase 3 melanoma trial, sending Moderna shares up over 120%.
Scientists discover first-ever contagious cancer in fish, a transmissible melanoma spreading among brown bullhead catfish in Lake Memphremagog.
Moderna and Merck's mRNA vaccine reduced melanoma recurrence risk by 49% over five years, offering new hope for advanced skin cancer patients.
A personalized mRNA cancer vaccine from Moderna and Merck reduced melanoma recurrence risk by 49% over five years, marking a major advance.
A personalized mRNA cancer vaccine combined with Keytruda reduced melanoma recurrence risk by 49% over five years, according to new clinical trial data.